ISIS Pharmaceuticals (ISIS) Hit Following Two-Notch Analyst Downgrade
Tweet
Share
E-mailGet Alerts ISIS Hot Sheet
Join SI Premium – FREE
ISIS Pharmaceuticals (Nasdaq: ISIS) is getting hit Thursday, following a two-notch downgrade at Jefferies, issued earlier.
Shares are over 9 percent lower on the session with volume over 500K shares so far.
Shares are over 9 percent lower on the session with volume over 500K shares so far.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Curium to acquire Lantheus in deal valued at up to $8 billion
- Lucid Group stock surges 24% on Saudi prince investment
- Jefferies has trade finance-related exposure of $300M to Radiant World - Reuters
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
